Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory P Geba

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
The Journal of Infectious Diseases|July 27, 2022
Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19Selin Somersan-Karakaya, Eleftherios Mylonakis, Vidya P Menon, et al.
The Lancet. Infectious Diseases|September 5, 2024
Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trialFlonza Isa, Ana M Gonzalez Ortiz, Jonathan Meyer, et al.
The New England Journal of Medicine|September 29, 2021
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19David M Weinreich, Sumathi Sivapalasingam, Thomas Norton, et al.
JAMA|January 14, 2022
Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical TrialMeagan P O'Brien, Eduardo Forleo-Neto, Neena Sarkar, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
The Journal of Infectious Diseases|July 27, 2022
Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19Selin Somersan-Karakaya, Eleftherios Mylonakis, Vidya P Menon, et al.
The Lancet. Infectious Diseases|September 5, 2024
Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trialFlonza Isa, Ana M Gonzalez Ortiz, Jonathan Meyer, et al.
The New England Journal of Medicine|September 29, 2021
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19David M Weinreich, Sumathi Sivapalasingam, Thomas Norton, et al.
JAMA|January 14, 2022
Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical TrialMeagan P O'Brien, Eduardo Forleo-Neto, Neena Sarkar, et al.
Pageof 7